NCT00603811View on ClinicalTrials.gov

Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Influenza Infection
Interventions
BIOLOGICAL

VAX102 [Flagellin.HuM2e]

dose ranging, 2 i.m. doses given 28 days apart

BIOLOGICAL

Placebo

Placebo

Trial Locations (2)

66219

Johnson County Clinical Trials, Lenexa

77555

Sealy Vaccine Center, UTMB, Galveston

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

VaxInnate Corporation

INDUSTRY

NCT00603811 - Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter